Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer

Roy Glen Wiggans, Paul V. Woolley, John S. Macdonald, Tarilyn Smythe, Winston Ueno, Philip S. Schein

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Ten of 23 patients with advanced measurable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF). The median duration of response is in excess of 7 months, and responding patients have lived significantly longer than patients with progressive disease (7.5+ months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30% of patients and persistent azotemia in 9% of patients.

Original languageEnglish (US)
Pages (from-to)387-391
Number of pages5
JournalCancer
Volume41
Issue number2
DOIs
StatePublished - Jan 1 1978

Fingerprint

Streptozocin
Pancreatic Neoplasms
Azotemia
Therapeutics
Proteinuria
Nausea
Vomiting
Pancreas
Adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer. / Wiggans, Roy Glen; Woolley, Paul V.; Macdonald, John S.; Smythe, Tarilyn; Ueno, Winston; Schein, Philip S.

In: Cancer, Vol. 41, No. 2, 01.01.1978, p. 387-391.

Research output: Contribution to journalArticle

Wiggans, Roy Glen ; Woolley, Paul V. ; Macdonald, John S. ; Smythe, Tarilyn ; Ueno, Winston ; Schein, Philip S. / Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer. In: Cancer. 1978 ; Vol. 41, No. 2. pp. 387-391.
@article{4b74163bf0ba4c7a815eedb32046b873,
title = "Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer",
abstract = "Ten of 23 patients with advanced measurable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF). The median duration of response is in excess of 7 months, and responding patients have lived significantly longer than patients with progressive disease (7.5+ months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30{\%} of patients and persistent azotemia in 9{\%} of patients.",
author = "Wiggans, {Roy Glen} and Woolley, {Paul V.} and Macdonald, {John S.} and Tarilyn Smythe and Winston Ueno and Schein, {Philip S.}",
year = "1978",
month = "1",
day = "1",
doi = "10.1002/1097-0142(197802)41:2<387::AID-CNCR2820410201>3.0.CO;2-X",
language = "English (US)",
volume = "41",
pages = "387--391",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer

AU - Wiggans, Roy Glen

AU - Woolley, Paul V.

AU - Macdonald, John S.

AU - Smythe, Tarilyn

AU - Ueno, Winston

AU - Schein, Philip S.

PY - 1978/1/1

Y1 - 1978/1/1

N2 - Ten of 23 patients with advanced measurable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF). The median duration of response is in excess of 7 months, and responding patients have lived significantly longer than patients with progressive disease (7.5+ months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30% of patients and persistent azotemia in 9% of patients.

AB - Ten of 23 patients with advanced measurable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF). The median duration of response is in excess of 7 months, and responding patients have lived significantly longer than patients with progressive disease (7.5+ months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30% of patients and persistent azotemia in 9% of patients.

UR - http://www.scopus.com/inward/record.url?scp=0017894379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017894379&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197802)41:2<387::AID-CNCR2820410201>3.0.CO;2-X

DO - 10.1002/1097-0142(197802)41:2<387::AID-CNCR2820410201>3.0.CO;2-X

M3 - Article

C2 - 147131

AN - SCOPUS:0017894379

VL - 41

SP - 387

EP - 391

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -